New class of drugs lowers cholesterol in first human trial

A new class of cholesterol-lowering drugs that target a recently discovered regulator of harmful cholesterol could be an alternative or complementary treatment for the 30 million people who take statins, after the first trial in humans confirms the technique's feasibility and safety. A single dose of the small interfering ribonucleic acid (siRNA) drug candidate ALN-PCS cut levels of LDL cholesterol (bad cholesterol) in healthy volunteers by up to 57%, and 40% on average more than those given a placebo, according to the new research published in The Lancet...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Cholesterol Source Type: news